echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The application for the listing of Qilu Pharmaceutical's Aiqupa ethanolamine tablets was accepted by CDE contractors

    The application for the listing of Qilu Pharmaceutical's Aiqupa ethanolamine tablets was accepted by CDE contractors

    • Last Update: 2021-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 20, Qilu Pharmaceuticals was accepted by CDE for a listing application for the generic 4-class declared Ayquopa ethanolamine tablet.
    meters of internal network forecast data show that 2020E China's urban physical pharmacy terminal Ayquopa ethanolamine tablet sales of nearly 300 million yuan, an increase of 67.92 percent year-on-year, replacing injection recombinant human coagulation factor VIII. became the best-selling anti-hemostamine.
    Source: CDE official website Acetopoethanolamine is an oral bioavailable, small molecule plate plateocyte production (TPO) receptor atrium that interacts with the transmeral domain of human TPO receptors and is clinically used in patients with plateiatric reduction and increased risk of bleeding due to clinical conditions.
    Aiqupopa ethanolamine tablets reported production source: Minet MED2.0 China's drug review database is currently only the original research manufacturers of Aiqupa ethanolamine tablets listed for sale, no generic drugs have been approved for listing, but there have been Osaikang, Zhengda Tianqing, Qilu 3 enterprises to copy 4 categories to submit the product listing application, the first imitation flower who fell? We will continue to pay attention.
    meters of intranet data show that in 2019, China's urban physical pharmacy terminal Ayquopa ethanolamine tablet sales reached 170 million yuan, up 289.63 percent year-on-year, forecast 2020 sales will reach 290 million yuan, up 67.92 percent year-on-year, replacing injection recombinant human coagulation factor VIII., became the best-selling anti-hemostamine drugstore drugstore.
    2020E China City Physical Pharmacy Terminal Hemostrheids TOP10 Product Source: Minet China City Physical Pharmacy Terminal Competition Pattern 2020E China City Physical Pharmacy Terminal Hemostred Drugs market concentration is relatively high, TOP10 products total market share of more than 90%.
    2 varieties of aiquopa ethanolamine tablets and pig-source fibrin adhesives increased significantly, with growth rate of more than 60%.
    From the 10 product ranking changes, Aiqupopa ethanolamine tablets instead of injection recombinant human coagulation factor VIII., became china's urban physical pharmacy terminal best-selling anti-hemostamine;
    source: MiNet database, CDE official website Note: Minet China's urban physical pharmacy terminal competition pattern database is covering 293 cities and above urban physical pharmacies (excluding county and rural physical pharmacies), the whole category of continuous monitoring of the enlarged version of the urban physical pharmacy database.
    sales are based on the average retail price of the product at the terminal.
    review data statistics as of January 20, if there are omissions, welcome to point out!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.